The HIV-1 reverse transcriptase genes from 37 HIV-1-positive pregnant women attending an antenatal clinical in Soweto, South Africa were sequenced and analyzed for the presence of drug resistance mutations. All women were antiretroviral drug naive, but were being screened as potential participants in clinical trials of antiretroviral drugs aimed at preventing mother-to-child transmission. Sequence analysis revealed that all belonged to HIV-1 subtype C, the predominant subtype among heterosexual populations in South Africa. Twentythree amino acid loci associated with resistance to zidovudine, lamivudine, didanosine, stavudine, and nevirapine were examined and found not to encode mutations that would confer resistance to these drugs. Polymorphisms at these loci occurred infrequently, with three patients harboring the A98S and V179I polymorphisms. An additional three patients harbored V118I, which can function as an accessory resistance mutation, but in this context is also likely to be a polymorphism. These data show that pregnant women who are candidates for receiving antiretroviral drug therapies do not contain naturally occurring or preexisting drug resistance mutations and that such drug therapies are likely to be highly effective in this setting.
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RUGS THAT TARGET the reverse transcriptase (RT) enzyme of the human immunodeficiency virus type 1 (HIV-1) have been shown to be highly effective in reducing the rates of mother-to-child transmission (MTCT). 1 Clinical trials have shown that short-course treatments with RT inhibitors, either singly or in combination, (such as zidovudine [AZT] , AZT plus lamivudine [3TC], didanosine [ddI] plus stavudine [d4T] or nevirapine [NVP] ) can reduce MTCT by up to 50%. [2] [3] [4] [5] Many of these regimens are being implemented in developing countries where MTCT is still a major route of infection. One of the potential obstacles to the continuing effectiveness of such interventions is the presence of drug resistance mutations. Resistance to all nucleoside and non-nucleoside RT inhibitors have been documented and shown to correlate with specific amino acid mutations in the RT gene (genotypic resistance). These mutations are identified by direct sequence analyses of viral genomes and correlate with the inability of these viruses to grow in vitro in the presence of these drugs (phenotypic resistance). A full compendium of these mutations is available for HIV-1 subtype B, the predominant subtype in the United States and Europe, where antiretroviral therapies have been in use for more than a decade. 6 There are limited data about HIV-1 subtype C viruses, largely because these viruses have not been widely exposed to antiretroviral therapies. 7, 8 Studies of HIV-1 subtype B viruses have shown that mutations associated with drug resistance are present in viral populations before their use. 9 This is due to the highly error-prone nature of reverse transcription, which introduces one error every replication cycle. Although naturally occurring mutations would occur at low frequencies these would be expected to expand once antiretroviral drugs were introduced. Data have shown that some subtype-specific polymorphisms encode mutations associated with antiretroviral drug resistance. 10 The impact of these naturally occurring polymorphisms is unknown but has raised the possibility that some drugs may show different levels of efficacy in patients infected with non-B subtypes or possibly that unique subtype-specific resistance patterns may emerge in patients failing therapy. Thus knowledge of baseline mutational patterns of different viral subtypes and within different populations is important to ascertain before the introduction of such therapies. In South Africa, antiretroviral therapy is not available through the public sector except in a small number of pilot sites conducting studies aimed at preventing MTCT. Here we examine the RT genes from HIV-1-positive pregnant women for mutations associated with resistance to drugs being used to prevent MTCT.
Blood samples were collected from drug-naive HIV-1-infected pregnant women attending an antenatal clinic at the Chris Hani Baragwanath Hospital in Soweto, outside Johannesburg, between October 2000 and November 2000. These women were being screened for enrollment into clinical trials of antiretroviral drug therapies to prevent MTCT. Informed consent was obtained from all participants and the protocol was approved by the Ethical Review Board of the University of the Witwatersrand for Research on Human Subjects (Medical). Whole blood was used to perform a CD4 1 T cell count (FACScount; Becton Dickinson, San Jose, CA) and then spun at 2000 rpm for 10 min to separate cells and plasma. Plasma virus was used for genetic analysis of the RT region of the pol gene as this provides a more accurate reflection of the replicating and potentially infectious viral species. Viral RNA was extracted from 140 ml of plasma, using a QIAamp viral RNA isolation kit (Qiagen, Valencia, CA), and reverse transcribed to cDNA using avian myeloblastosis virus (AMV) reverse transcriptase at 42°C for 1 hr with outer primers designed using subtype C sequences: HB1F (59-CAA GGG GAG GCC AGG GAA TTT-39) and HB1R (59-TAT TTC AGC TAT CAA GTC TTT TGA TGG GTC A-39). The cDNA was then subjected to a nested PCR using inner primers pol1F (59-TTT TCC CAT TAG TCC TAT TGA AAC TGT A-39) and pol1R (59-CAT GCT ACT CTG GAA TAT TGC TGG TGA TCC-39), which generates an ,495-bp fragment, and pol2F (59-CTG CAT TCA CCA TAC CTA GTA TAA AC-39) and pol2R (59-TGA TGG GTC ATA ATA TAC TCC ATG-39), which generates an ,583-bp fragment. The inner primer pairs have been used previously to amplify these regions of pol from plasma samples derived from several cohorts infected with HIV-1 subtype C (C. Williamson and R. Swanstrom, unpublished). The resulting two fragments overlap and span the drug resistance loci of the HIV-1 RT gene, and yield an ,969 bp region corresponding to nucleotides 2546-3515 of the HXB2 genome. The following cycling conditions were used in the first round: 94°C for 4 min followed by 30 cycles of 94°C for 1 min, 55°C for 1 min, and 72°C for 2 min, ending with an extension at 72°C for 7 min. Secondround PCR was 30 cycles at 94°C for 1 min, 55°C for 1 min, followed by 72°C for 7 min. Reactions made use of SuperTherm DNA polymerase and a PerkinElmer (Norwalk, CT) 9700 PCR machine. Second-round PCR products were purified with a High Pure PCR product purification kit (Boehringer GmbH, Mannheim, Germany). Primers pol1 and pol2 were used for the sense and antisense strand-sequencing reactions, under the following conditions: 96°C for 10 sec, 50°C for 5 sec, and 60°C for 4 min for 25 cycles. Sequence products were purified with Centri-Sep columns (Applied Biosystems, Foster City, CA) before loading onto an ABI-3100 genetic analyzer. Predicted amino acid translations were done with CLUSTAL W and characteristic amino acid mutations at particular loci were examined. In addition, sequences were analyzed by using an HIV search engine for queries (HIV-SEQ) in the Stanford HIV RT and protease sequence database for confirmation (www.hivdb.stanford.edu/hiv/).
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A total of 37 RT sequences were obtained from 52 samples, using a nested polymerase chain reaction (PCR) with subtype C-specific primers. The reasons why the remaining 15 plasma samples did not amplify was not explored but may be related to low viral load or possibly primer mismatches. The median CD4
1 cell count for these 37 women was 479 cells/ml (range, 105-1505), indicating that they were mostly asymptomatic. Analysis of nucleotide sequences by the Stanford database and phylogenetic analysis using PHYLIP revealed that all grouped with HIV-1 subtype C, the predominant subtype in heterosexual populations in South Africa (data not shown). The predicted 298-amino acid sequences (positions 10-308) from all 37 samples were used to generate a consensus sequence and to determine the presence of the known drug resistance mutations for ZDV (M41L, D67N, K70R, L210W, T215Y/D/A/F/S, K219E/Q), 3TC (M184I/T/V), ddI (K65R, L74V, M184V), d4T (V75T), multiple nucleosides (T69A/D/N, V118I, Q151M), and NVP (A98G, L100I, K101E, K103N, V106A, V108I, V179D/E, Y181C/I, Y188C, and G190A) (highlighted in gray in Fig. 1) . None of the 37 viral sequences analyzed were shown to harbor any of these mutations and would therefore be expected to be fully sensitive to the various drugs. Three sequences, AC1, AC4, and AC47, harbored the V118I mutation that can confer resistance when present with E44A/D but in its absence is considered to be a polymorphism. A similar frequency of V118I was found among untreated individuals infected with HIV-1 subtype B (R. Kantor, personal communication). Two other polymorphisms that are not associated with drug resistance were present in three samples: AC11 and AC49 (V179I), and AC45 (A98S) (Fig. 1) . A98S is a naturally occurring polymorphism also found infrequently among untreated HIV-1 subtype B-infected individuals (R. Kantor, personal communication). All 37 amino acid sequences were highly related and were 96.6-99.3% homologous. The first 150 amino acids were more conserved, particularly the region between amino acids 41 and 117, which were identical for 35 of the 37 sequences. Most of the variation was found between amino acids 170 and 300. At least seven loci, at positions 123, 173, 174, 207, 214, 245, and 272, were found to have a high degree of variation that is typical for RT sequences of all subtypes (Los Alamos HIV Sequence Database, http://hiv-web.lanl.gov). Two sequences were found to have single deletions, at positions 129 and 130, but all others were 298 amino acids in length. Although there was no evidence of drug resistance mutations among these sequences, population-based sequencing would detect only the major species and a more detailed analysis of the various quasispecies needs to be done to confirm that drugresistant variants do not constitute a minor species.
These data indicate that drug-resistant viruses are not prevalent among HIV-1-positive pregnant women in South Africa and that naturally occurring polymorphisms would not compromise the efficacy of RT inhibitors aimed at preventing MTCT. This is not unexpected given that these women have not been exposed to antiretroviral therapy, but is nevertheless important to establish because of reports of subtype-specific polymorphisms. 10 
FIG. 1. Continued.
viral therapies, such as AZT plus 3TC, ddI plus d4T, and NVP, to prevent MTCT. 3, 4, 12 Despite this, MTCT remains a major route of infection in South Africa, where 23% of pregnant women are HIV-1 positive and an estimated 70,00-80,000 HIVinfected infants are born annually. 13 The nationwide introduction of antiretroviral therapies would have a major impact on curbing transmission of HIV-1 via this route. The absence of drug resistance mutations suggests that these interventions would not be compromised in the short term. However, it will be important to continue monitoring women entering these programs, as a high level of resistant mutations would impact on the effectiveness of such interventions in the future.
MTCT studies conducted in Uganda have shown that drug resistance mutations are present in maternal and infant viral sequences after a single dose of NVP.
14 These mutations were not associated with failure to prevent MTCT and so their significance as yet remains unclear. Interestingly, resistance mutations were more prevalent among HIV-1 subtype D than subtype A sequences. 15 Because there were no HIV sequence data available from this cohort before receiving antiretroviral therapy, it is not possible to determine whether these mutations were preexisting. Nevertheless, these data suggest that naturally occurring subtype-specific polymorphisms may predispose some viruses to develop drug-resistant mutations more rapidly. At this stage the propensity of subtype C viruses to do this is unknown and awaits study. It remains to be seen what level of resistance is induced in subtype C-infected women and infants after a single dose of NVP and what, if any, effect this has on the long-term outcome of their HIV disease, their subsequent treatments, and pregnancies. These data thus provide important background information for future MTCT intervention studies involving NVP, because they indicate that polymorphisms associated with NVP resistance are not common among subtype C sequences from pregnant women living in South Africa.
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